(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Poland Crypto Bill Clears Sejm Again, Defying President — Will “Restrictive” Rules Stick? - 241 Young Men Die in South Africa After Circumcision Initiation
- 3This Tiny Bright Yellow Frog Is One of the Most Toxic Animals on Earth
- 4India's top court hears challenges to ruling on women's entry into temple
- 5China bans storing cremated remains in empty 'bone ash apartments'
- Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- Survey: Canteen Cups With Great Warm Protection Impact
- Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- 12 Once-In-A-Lifetime Travel Experiences To Add to Your Bucket List
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
